Imatinib
Checked 2026-09-09
Chronic-phase CML; adjuvant GIST for 3 years after resection of high-risk tumours; metastatic GIST
One cycle
every 28 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Imatinib Small-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA) | 400 mg once daily with food (600-800 mg for KIT exon 9 GIST or accelerated phase) | Oral | D1-28 |
Cycles
indefinite (CML; treatment-free remission in deep response); 3 years adjuvant GIST
28-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Used in
Products
Source
IRIS, NEJM 2003; SSGXVIII/AIO, JAMA 2012
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Sunitinib 4/2
Advanced clear-cell RCC favourable risk or when immunotherapy is contraindicated; imatinib-resistant GIST; pancreatic NET
every 42 days
Blinatumomab
B-ALL: MRD-positive, relapsed/refractory, or consolidation in frontline regimens (E1910, AALL1731)
every 42 days × 2
Inotuzumab ozogamicin
Relapsed or refractory CD22-positive B-ALL
every 21 days
Fludarabine + cyclophosphamide lymphodepletion, then CD19 CAR-T
Relapsed or refractory large B-cell lymphoma (second line if refractory or relapse within 12 months), B-ALL, follicular and mantle cell lymphoma
every 6 days